KR20250006145A - 근시를 예방 또는 치료하기 위한 방법 및 조성물 - Google Patents

근시를 예방 또는 치료하기 위한 방법 및 조성물 Download PDF

Info

Publication number
KR20250006145A
KR20250006145A KR1020247038134A KR20247038134A KR20250006145A KR 20250006145 A KR20250006145 A KR 20250006145A KR 1020247038134 A KR1020247038134 A KR 1020247038134A KR 20247038134 A KR20247038134 A KR 20247038134A KR 20250006145 A KR20250006145 A KR 20250006145A
Authority
KR
South Korea
Prior art keywords
lactic acid
myopia
acid bacteria
choroid
resident immune
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020247038134A
Other languages
English (en)
Korean (ko)
Inventor
카즈오 츠보타
토시히데 쿠리하라
신이치 이케다
징 호우
Original Assignee
가부시키가이샤 쓰보타 라보
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 가부시키가이샤 쓰보타 라보 filed Critical 가부시키가이샤 쓰보타 라보
Publication of KR20250006145A publication Critical patent/KR20250006145A/ko
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/18—Peptides; Protein hydrolysates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00—Function of food ingredients
    • A23V2200/30—Foods, ingredients or supplements having a functional effect on health
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2400/00—Lactic or propionic acid bacteria
    • A23V2400/11—Lactobacillus
    • A23V2400/165—Paracasei

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Polymers & Plastics (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Ophthalmology & Optometry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020247038134A 2022-04-26 2023-04-25 근시를 예방 또는 치료하기 위한 방법 및 조성물 Pending KR20250006145A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2022072596 2022-04-26
JPJP-P-2022-072596 2022-04-26
PCT/JP2023/016344 WO2023210657A1 (ja) 2022-04-26 2023-04-25 近視を予防または治療するための方法および組成物

Publications (1)

Publication Number Publication Date
KR20250006145A true KR20250006145A (ko) 2025-01-10

Family

ID=88519036

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020247038134A Pending KR20250006145A (ko) 2022-04-26 2023-04-25 근시를 예방 또는 치료하기 위한 방법 및 조성물

Country Status (9)

Country Link
EP (1) EP4516305A4 (https=)
JP (3) JP7713267B2 (https=)
KR (1) KR20250006145A (https=)
CN (1) CN119072322A (https=)
AU (1) AU2023258808A1 (https=)
CA (1) CA3249939A1 (https=)
MX (1) MX2024013133A (https=)
TW (1) TW202400198A (https=)
WO (1) WO2023210657A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025089394A1 (ja) * 2023-10-25 2025-05-01 株式会社坪田ラボ 近視を予防または治療するための方法および組成物
JP7781461B2 (ja) 2023-10-25 2025-12-08 株式会社坪田ラボ 近視を予防または治療するための方法および組成物
WO2025192737A1 (ja) * 2024-03-15 2025-09-18 株式会社坪田ラボ 脈絡膜菲薄化抑制剤

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3066561B2 (ja) * 1993-10-07 2000-07-17 武田薬品工業株式会社 近視予防・治療剤
TWI658828B (zh) * 2014-10-31 2019-05-11 中國醫藥大學 用於舒緩及減輕近視之醫藥組合物及其製備方法與用途
JP6640803B2 (ja) * 2016-09-09 2020-02-05 キリンホールディングス株式会社 眼疲労の抑制又は改善用組成物
WO2018164113A1 (ja) * 2017-03-06 2018-09-13 学校法人 慶應義塾 マウス近視誘導モデル及び近視予防・抑制のための小胞体ストレス抑制剤
CN107372821A (zh) * 2017-07-25 2017-11-24 芜湖职业技术学院 护眼保健酸奶及其制备方法
CN116568314A (zh) * 2020-09-23 2023-08-08 Pbl生物实验室 新型乳酸菌及其用途
JP7394737B2 (ja) 2020-10-30 2023-12-08 愛三工業株式会社 燃料供給装置
CN112493318A (zh) * 2020-12-01 2021-03-16 河北三元食品有限公司 一种专用于三周岁以上儿童的全营养奶粉及其制备方法
CN113349257A (zh) * 2021-04-13 2021-09-07 石家庄君乐宝乳业有限公司 一种有益于视力保护的发酵乳及其制备方法

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
Biofactors. 2023 Feb 6. doi: 10.1002/biof.1942.
Elife. 2020 Apr 1;9:e55564.
Eur J Pharmacol. 2012 Jan 15;674(2-3):391-6.
FASEB J. 2020 Aug;34(8):10117-10131.
Jiang et al. Proc Natl Acad Sci USA. 2021. 1;118(22):e2018840118.
Mori et al., Sci Rep. 2019. 22;9(1):295.
Oxid Med Cell Longev. 2021 Sep 10;2021:6631929.

Also Published As

Publication number Publication date
MX2024013133A (es) 2024-12-06
JP7808901B2 (ja) 2026-01-30
CN119072322A (zh) 2024-12-03
JPWO2023210657A1 (https=) 2023-11-02
JP2025129384A (ja) 2025-09-04
EP4516305A4 (en) 2026-04-08
WO2023210657A1 (ja) 2023-11-02
EP4516305A1 (en) 2025-03-05
CA3249939A1 (en) 2025-06-17
JP7713267B2 (ja) 2025-07-25
AU2023258808A1 (en) 2024-11-07
JP2026063064A (ja) 2026-04-10
TW202400198A (zh) 2024-01-01

Similar Documents

Publication Publication Date Title
KR20250006145A (ko) 근시를 예방 또는 치료하기 위한 방법 및 조성물
RS57138B1 (sr) Kompozicije koje sadrže bakterijske sojeve
KR101778734B1 (ko) 비피도박테리움 롱검 kacc 91563으로부터 분리된 esbp 및 이를 이용한 항알레르기 조성물
KR20190133639A (ko) 락토바실러스 크리스파투스 kbl693 균주 및 그 용도
TW202038978A (zh) 包含細菌菌株之組成物
Abdelazez et al. Verification of Lactobacillus brevis tolerance to simulated gastric juice and the potential effects of postbiotic gamma-aminobutyric acid in streptozotocin-induced diabetic mice
TW201532609A (zh) 乳酸菌、其組合物與彼等於治療自體免疫疾病暨其倂發症之用途
JP2018503597A (ja) その必要がある対象の飽食を誘導し、満腹を延長させる医薬組成物および食品組成物
JP2018503597A5 (https=)
JP2020162479A (ja) 目の不調を改善する組成物及びその利用
CN116004472A (zh) 一株缓解肥胖的丁酸梭菌及其应用
KR20180110848A (ko) 신규한 락토바실러스 루테리 균주 및 그 프로바이오틱 용도
CN115776986A (zh) 新型蛋白质及其治疗和美容用途
HK40112500A (zh) 用於预防或治疗近视的方法及组合物
KR102260116B1 (ko) 항균 펩타이드 회피 유전자를 포함하는 재조합 바실러스 칼메트-게렝균의 방광암 항암 치료용 약학적 조성물
WO2025089394A1 (ja) 近視を予防または治療するための方法および組成物
EP4527398A1 (en) Therapeutic use of a postbiotic composition in colon and or lung cancer
US7862809B2 (en) Use of strains of lactobacillus and by-products thereof for inhibiting formation of blood vessels
JP7725011B1 (ja) Ｃｄ４－ｃｄ８－ｔ細胞を増殖および／または活性化させるための組成物
JP7835954B2 (ja) 乳酸菌及び免疫賦活剤
RS53996B1 (sr) Kompozicije koje sadrže core-1 pozitivni mikroorganizam i njihova primena za lečenje ili profilaksu tumora
EP4687929A1 (en) Postbiotic composition comprising bacterial lysates for oral administration for treating solid tumors
Giampapa Hormones: Basic Concepts and Cell Signaling
CN117618473A (zh) Pb菌在预防、改善和治疗代谢性疾病中的应用
AU2013206647A1 (en) Methods and compositions for extending the life span and increasing the stress resistance of cells and organisms

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E13 Pre-grant limitation requested

Free format text: ST27 STATUS EVENT CODE: A-2-3-E10-E13-LIM-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

D16 Fast track examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D16-EXM-PA0302 (AS PROVIDED BY THE NATIONAL OFFICE)

PA0302 Request for accelerated examination

St.27 status event code: A-1-2-D10-D16-exm-PA0302